GERD from gastro intestinal tract
GERD gastroesophageal reflux disease pathophysiology diagnosis management
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 8868
GERD gastroesophageal reflux disease esophagus anatomy

Hugging Face pmc clinical VQA raw
Page 0
| Mechanism | Description |
|---|---|
| Transient LES Relaxations (TLESRs) | The most common cause; LES relaxes independent of swallowing, allowing reflux |
| Hypotensive LES | Persistently low resting LES pressure (<10 mmHg) |
| Hiatal Hernia | Displaces the LES above the diaphragm, disrupting the anti-reflux barrier |
| Impaired Esophageal Clearance | Reduced peristalsis prolongs acid exposure time |
| Delayed Gastric Emptying | Increases intragastric pressure and volume |

| Intervention | Rationale |
|---|---|
| Elevate head of bed 6–8 inches | Reduces nocturnal reflux |
| Avoid lying down within 3 hrs of eating | Reduces postprandial reflux |
| Weight loss | Decreases intraabdominal pressure |
| Avoid triggers (fatty foods, caffeine, alcohol, chocolate, mint) | Reduces LES relaxation |
| Smoking cessation | Improves LES tone |
| Drug Class | Examples | Notes |
|---|---|---|
| PPIs (first-line) | Omeprazole, Pantoprazole, Esomeprazole | Taken 30–60 min before meals; most effective acid suppression |
| H2 Receptor Antagonists | Famotidine, Ranitidine | Second-line or add-on for nocturnal breakthrough |
| Antacids/Alginates | Tums, Gaviscon | Rapid but short-lived symptom relief |
| Prokinetics | Metoclopramide | Rarely used; side-effect profile limits use |
| Finding | Surveillance Interval |
|---|---|
| No dysplasia | Every 3–5 years |
| Low-grade dysplasia | Every 6–12 months or endoscopic eradication therapy |
| High-grade dysplasia | Endoscopic eradication therapy (RFA, EMR) |